Sesen Bio Inc (SESN)

[Meztic]

EBIO DD PACKET – More Coming!

Cash Position

As of December 31, 2015, Eleven had approximately $36.1 million of cash and cash equivalents. As a result of the outcome of this trial, Eleven is required to fund a cash collateral account with Silicon Valley Bank in an amount equal to approximately $15.1 million, representing the outstanding amounts under its loan agreement with Silicon Valley Bank.

Eleven Biotherapeutics currently expects its unrestricted cash and cash equivalents will enable the Company to fund its operating plans into the fourth quarter of 2016.

SOURCE: http://ir.elevenbio.com/releasedetail.cfm?ReleaseID=950518

POSSIBLE SOURCES OF NEW REVENUE


“The deal between Albumedix and Eleven Biotherapeutics was completed on 4 December 2015. The terms of the agreement are not disclosed but under the agreement, Albumedix will pay Eleven an upfront fee as well as a share of commercialization income.”

SOURCE: http://ir.elevenbio.com/releasedetail.cfm?ReleaseID=951783

NEW DRUG THEY ARE WORKING ON

About EBI-031

"Eleven Biotherapeutics' most advanced preclinical product candidate is EBI-031 for treatment of diabetic macular edema, or DME, and uveitis. EBI-031 was designed and engineered for intravitreal delivery using the Company's AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R) and has demonstrated a longer vitreal retention time in preclinical models than antibodies and antibody like molecules approved for intravitreal injection."

"The Company is undertaking manufacturing development work and nonclinical safety studies to support the submission of an investigational new drug application, or IND, to the FDA in the first half of 2016 for the purpose of conducting clinical trials of EBI-031 in DME and uveitis."

EBI-031 TIMELINE - http://elevenbio.com/pipeline/pipeline.html

WHEN SHOULD WE GET AN UPDATE- SEE EMAIL BELOW

Compliments of poster Bradley

Hi Bradley,

In our press release dated 1/15/16, we said that we would provide an update on our Corporate strategy during our 2015 year end financial results announcement. That will occur this month, so I recommend you look for that announcement as an update.

Thank you,
Leah